EDAP TMS (FocalTherics) launches ADS offering, stock falls 19.6%

What happened

EDAP TMS S.A., a French medical device company operating under the commercial name FocalTherics, filed a preliminary prospectus supplement with the SEC on August 12, 2026, to offer American Depositary Shares (ADSs). Each ADS represents one ordinary share with a nominal value of €0.13. The offering is part of a 'shelf' registration statement filed on Form S-3 that became effective March 31, 2026.

The company's stock fell sharply on the announcement. On August 12, 2026, the ADSs closed at $4.83, down 19.63% from the prior close of $6.01. Trading volume was 1,022,194 shares, about 21 times the average volume of 48,755. The last reported sale price before the offering was $6.08 on August 10, 2026.

The prospectus supplement does not specify the number of ADSs to be offered or the offering price; those details are left blank in the filing. The filing notes that the underwriters have a 30-day option to purchase additional ADSs, but the number is also not stated.

Why this matters

The company is a 'smaller reporting company' under SEC rules. It develops and sells high-intensity focused ultrasound (HIFU) devices and is discontinuing its extracorporeal shock wave lithotripsy (ESWL) and distribution segments, according to risk factors in the filing.

This is a 'shelf takedown.' The company had already registered a pool of securities with the SEC under a shelf registration. This filing, on Form 424B5, is the specific prospectus supplement that allows it to sell new ADSs from that shelf. It is a capital raise, meaning the company will issue new shares and receive proceeds.

The sharp price drop and high volume are consistent with the market reaction to a new share offering, which typically dilutes existing shareholders. The filing itself does not explain the price drop, but the timing — the offering was announced the same day — is telling.

What this means

This is a preliminary prospectus supplement, not the final one. That means the terms — number of shares, price, commissions — are not yet set. The company and underwriters (TD Cowen, Mizuho, H.C. Wainwright & Co., and Lucid Capital Markets) will finalize those terms in a subsequent final prospectus.

The offering is an 'underwritten offering.' The underwriters will buy the ADSs from the company and resell them to investors. The company will use the proceeds as described in the 'Use of Proceeds' section, which is not detailed in the excerpt but will be in the full filing.

The ADSs are American Depositary Shares. They represent ownership in the ordinary shares of EDAP TMS, which is a French company. Each ADS equals one ordinary share. The company's reporting currency is the U.S. dollar, but its functional currency is the euro.

Investors should expect the offering to be completed soon, possibly within days. The settlement cycle is noted as T+2, meaning delivery of the ADSs occurs two business days after the trade date, as stated in the filing.